Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Bioceltix S.A. Logo
Developing 'off-the-shelf' stem cell therapies for diseases in companion animals.
Poland BCX
Biofarm S.A. Logo
A top domestic manufacturer of pharmaceuticals, supplements, and soft gelatin capsules.
Romania BIO
Biofrontera AG Logo
Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.
Germany B8F
BioGaia Logo
Develops and commercializes clinically proven probiotics for digestive health across all life stages.
Sweden BIOG
Bio-Gate AG Logo
Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.
Germany BIG1
BioInfra Co.,Ltd. Logo
Offers cancer screening blood tests and provides CRO services to the pharmaceutical industry.
South Korea 199730
BioInfra Life Science Inc. Logo
Biotech specializing in oncology diagnostics and R&D for cancer gene treatments.
South Korea 266470
BioInvent International Logo
Develops first-in-class immuno-modulatory antibodies for cancer therapy.
Sweden BINV
BioLineRx Ltd. Logo
Biopharma firm developing and commercializing therapies for cancer and rare diseases.
Israel BLRX
BioMaxima S.A. Logo
Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.
Poland BMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.